New Delhi: India, which is under the second wave of corona epidemic, may soon get another vaccine. Zayedus Cadila (Zydus Cadila) has sought permission from the Drug Controller General (DCGI) for trial of antibody cocktails for treatment of patients with mild targets of corona virus. Tell us that Zayedus is the only Indian company to develop monoclonal antibody based cocktails to treat corona infections.

Zayedus Cadila informed that the company has sought permission to DCGI for clinical trials for monoclonal antibody cocktails. Tell us that it is a cocktail of two monoclonal antibodies, which mimics natural antibodies, which causes the body to fight infection. Dr. Sharvil Patel, MD, Zayedus Healthcare Limited, said, "At this juncture, we need to find safer and more effective treatments to deal with corona. It is important to look at the various stages of the disease's progress and find options that can reduce the patient's pain and problem.

Earlier, the country's renowned pharmaceutical companies Rosh India and Cipla announced the launch of the antibody cocktail on Monday. One dose is priced at Rs 59,750 and will be given to patients infected at a light and medium level at high risk. This antibody cocktail is a mixture of two medicines casirivimeb and imdevimab. It has one lakh packs in India. There are two doses in a pack, thus benefiting two lakh patients.

Palestinian President calls for International peace track to end Israeli occupation

`The Retirement Plan`: Nicolas Cage among cast for action-thriller

Delhi HC's question to the Center, 'Why so much tax on drugs of black fungus?'